. 2023 Jan 12;15(2):483. doi: 10.3390/cancers15020483

Table 4.

Characteristics of studied pharmacotherapeutic regimens.

Agent	Dosage	Partial Radiographic Response (Range)	Stable Radiographic Response (Range)	6-Month Progression-Free Survival (Range)	Common Grade III/IV/V Toxicities
*Chemotherapy*
Hydroxyurea	15–30 mg/kg/d 1000–1500 mg/d	0–10%	0–88%	85%	Hematological, dermatological
Temozolomide	50–75 mg/m²/d	0	81.25%	N/A	Hematological, constitutional, neurological
Irinotecan	350–600 mg/m²/d	0	81%	6%	GI/hematological
Cyclophosphamide Doxorubicin Vincristine	500 mg/m²/d 15 mg/m²/d 1.4 mg/m²/d	21%	79%	N/A	N/A
Imatinib	500–800 mg/d	0	47.3–100%	N/A	Hematological, fluid and electrolytes
Gefitinib Erlotinib	500–1000 mg/d 150 mg/d	0	32%	28%	N/A
Vatalanib	500–1000 mg/d	N/A	N/A	37.5–64.3%	Hepatic, constitutional
Sunitinib	50 mg/d	5.55%	69.4%	42%	Hemorrhagic/thrombotic events
Hydroxyurea Imatinib	1000 mg/d 400–600 mg/d	0	57.1–66.6%	61.9%	Hematological
Everolimus	10 mg/d for 10 d preoperatively	N/A	N/A	N/A	None
*Hormonal therapy*
Octreotide	500 mg/d (regular) 30–60 mg monthly (LAR)	0	33.33–75%	32–44.4%	Hematological, metabolic, constitutional
90Y-DOTATOC 177Lu-DOTATOC	3 d every 6 or more wk	0	65.6%	N/A	Hematological, renal
Mifepristone	200 mg/d	1.4–30.76%	38.46–55%	N/A	N/A
Tamoxifen	10–30 mg/d	5–16.66%	32–50%	100%	N/A
Medroxyprogestrone acetate	1000 mg weekly	0	N/A	80%	N/A
Megestrol acetate	160–320 mg/d	0	N/A	N/A	N/A
*Biologic agents*
Interferon a	1,500,000–5,000,000 IU/d 10,000,000 U/m² every other day	0	74.28%	54%	N/A
*Combined regimens*
Bevacizumab Everolumus, P.O. on days 1/15 of 28d cycles	10 mg/kg 10 mg/d	0	88%	69%	Hematological, metabolic, renal, GI
Octreotide LAR Everolimus	30 mg monthly 10 mg/d	0	N/A	55%	Stomatitis

Dd, day; wk, week(s); G.I., gastrointestinal; LAR, long-acting releasing.